Clinical Trials


Home Clinical Trials Plegridy Study


Not open to enrollment... The use of Plegridy (PEGylated interferon beta-1a) in patients with Multiple Sclerosis (POP Study)

Posted March 17, 2016 by Jeneane Nichol Henry

The main objective of this study is to determine the incidence of serious adverse events (SAEs) in patients with relapsing forms of MS in routine clinical practice and to assess the overall long-term effectiveness of Plegridy in patients with relapsing forms of MS in routine clinical practice, including prescription and utilization adherence patterns and patient reported outcomes and tolerability of the use of Plegridy.

 

ENROLLMENT CLOSING 1/13/2017

 

To qualify, patients must:

PATIENTS DO NOT HAVE TO BE NAIVE TO PLEGRIDY IN ORDER TO QUALIFY FOR THE STUDY.

 


Patients will be followed for up to 5 years and will be asked to complete approximately 5-6 electronic questionnaires after their routine clinic visits.

For more information, please contact Jeneane Henry, RN BSN, Clinical Research Nurse at 804-828-7802 or jeneane.henry@vcuhealth.org.

 

Investigators:

Warren L. Felton III, MD (Principal Investigator), Dept. of Neurology at VCU

Unsong Oh, MD (Sub-Investigator), Dept. of Neurology at VCU

 

Clinical Research Nurse / Study Coordinator:

Jeneane Henry, RN BSN, Dept. of Neurology at VCU